Mirum Pharmaceuticals, Inc. announced the completion of enrollment in the Phase 2b VISTAS study of volixibat. This investigational oral IBAT inhibitor is being evaluated for the treatment of cholestatic pruritus in patients with primary sclerosing cholangitis (PSC).
The VISTAS trial had previously met its pre-specified efficacy and safety thresholds during a blinded interim analysis for dose selection conducted in 2024. Completing enrollment is a critical step in the clinical development process, moving the study closer to its conclusion.
Topline results from the VISTAS study are expected to be announced in the second quarter of 2026. This milestone de-risks the trial timeline and sets a clear path for future data readouts, which are important catalysts for the company's pipeline.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.